Ratings by Citi (Geoff Meacham)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/15/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 7/15/2026 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 5/18/2026 | Regeneron Pharma | REGN | Downgrade | Neutral (Buy) |
712.87 (676.69) |
-5.08% | Details | |
| 5/6/2026 | Merck | MRK | New Coverage | Neutral (N/A) |
113.15 (127.50) |
12.68% | Details | |
| 4/27/2026 | Veradermics | MANE | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2026 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2026 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2026 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2026 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2026 | Veradermics | MANE | New Coverage | Buy (N/A) |
45.85 (111.32) |
142.79% | Details | |
| 1/28/2026 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2026 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2026 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2026 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2026 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2026 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/9/2026 | Vor Biopharma, Inc. | VOR | New Coverage | Buy (N/A) |
12.78 (18.09) |
41.55% | Details | |
| 1/9/2026 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
41.67 (52.86) |
26.85% | Details | |
| 12/8/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 12/2/2025 | Pfizer | PFE | New Coverage | Neutral (N/A) |
25.74 (25.05) |
-2.68% | Details | |
| 11/12/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2025 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2025 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2025 | Avidity Biosciences | RNA | Downgrade | Neutral (Buy) |
49.15 (12.15) |
-75.28% | Details | |
| 10/27/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2025 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Kiniksa | KNSA | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2025 | Merck | MRK | New Coverage | Neutral (N/A) |
85.99 (113.15) |
31.59% | Details | |
| 10/8/2025 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 10/2/2025 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/25/2025 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/22/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/14/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2025 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2025 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
54.66 (140.91) |
157.79% | Details | |
| 6/17/2025 | Novavax | NVAX | New Coverage | Sell (N/A) |
7.03 (8.21) |
16.79% | Details | |
| 6/17/2025 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Buy (N/A) |
19.75 (31.68) |
60.41% | Details | |
| 6/17/2025 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
64.09 (115.07) |
79.54% | Details | |
| 6/17/2025 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
5.44 (17.75) |
226.29% | Details | |
| 6/17/2025 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Buy (N/A) |
1.14 (2.25) |
97.37% | Details | |
| 6/2/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 6/2/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/14/2025 | Merck | MRK | Downgrade | Neutral (Buy) |
76.63 (85.99) |
12.21% | Details | |
| 5/14/2025 | Abbvie | ABBV | Downgrade | Neutral (Buy) |
188.00 (254.49) |
35.37% | Details | |
| 5/14/2025 | Regeneron Pharma | REGN | Upgrade | Buy (Neutral) |
574.16 (676.69) |
17.86% | Details | |
| 5/7/2025 | PTC Therapeutics | PTCT | Upgrade | Neutral (Sell) |
40.65 (70.87) |
74.34% | Details | |
| 5/5/2025 | BioNTech | BNTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/11/2025 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 4/3/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/25/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2025 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2025 | PTC Therapeutics | PTCT | New Coverage | Sell (N/A) |
53.61 (40.65) |
-24.17% | Details | |
| 3/13/2025 | Moderna | MRNA | New Coverage | Neutral (N/A) |
35.01 (61.82) |
76.58% | Details | |
| 3/13/2025 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
35.10 (115.77) |
229.83% | Details | |
| 3/13/2025 | Kiniksa | KNSA | New Coverage | Buy (N/A) |
22.50 (63.95) |
184.22% | Details | |
| 3/13/2025 | BioNTech | BNTX | New Coverage | Buy (N/A) |
100.31 (91.48) |
-8.8% | Details | |
| 3/13/2025 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
32.61 (49.15) |
50.72% | Details | |
| 3/13/2025 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
38.53 (134.00) |
247.78% | Details | |
| 3/13/2025 | 89bio Inc. | ETNB | New Coverage | Buy (N/A) |
8.35 (14.84) |
77.72% | Details | |
| 1/28/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 1/15/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2024 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2024 | Vertex | VRTX | New Coverage | Buy (N/A) |
490.00 (485.65) |
-0.89% | Details | |
| 11/14/2024 | Gilead Sciences | GILD | New Coverage | Buy (N/A) |
94.35 (134.28) |
42.32% | Details | |
| 11/14/2024 | Biogen | BIIB | New Coverage | Neutral (N/A) |
168.28 (205.99) |
22.41% | Details | |
| 11/14/2024 | Amgen | AMGN | New Coverage | Neutral (N/A) |
298.84 (366.29) |
22.57% | Details | |
| 10/25/2024 | Royalty Pharma | RPRX | New Coverage | Buy (N/A) |
27.28 (58.18) |
113.27% | Details | |
| 10/25/2024 | Pfizer | PFE | New Coverage | Neutral (N/A) |
28.64 (25.74) |
-10.13% | Details | |
| 10/25/2024 | Merck | MRK | New Coverage | Buy (N/A) |
105.88 (76.63) |
-27.63% | Details | |
| 10/25/2024 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
891.32 (1179.11) |
32.29% | Details | |
| 10/25/2024 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (N/A) |
52.92 (60.74) |
14.78% | Details | |
| 10/25/2024 | Abbvie | ABBV | New Coverage | Buy (N/A) |
189.65 (188.00) |
-0.87% | Details |
